The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.50
Bid: 19.00
Ask: 20.00
Change: -0.50 (-2.50%)
Spread: 1.00 (5.263%)
Open: 19.50
High: 20.00
Low: 19.50
Prev. Close: 20.00
IOF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Corporate Update

18 Jan 2016 07:00

RNS Number : 1092M
Iofina PLC
18 January 2016
 

 

18 January 2016

Iofina plc

("Iofina" or the "Company")

(LSE AIM: IOF)

 

Corporate Update

Annualised iodine production increase of over 73%

 

Iofina, specialists in the exploration and production of iodine and iodine specialty chemical derivatives, today provides an update to the market regarding record crystalline iodine production totals in 2015.

 

During the period, Iofina produced a total of 569.1 metric tonnes ("MT") of crystalline iodine (2014: 327.7MT) from its IOsorb® plants. Although the Company experienced power outages at its IOsorb® plants and at its partners' operations due to adverse weather conditions in late December, resulting in a loss of anticipated production of about 5-7MT of crystalline iodine in the month, the Board is pleased with the like-for-like increase of over 73% of crystalline iodine from our IOsorb® facilities in its core area in Oklahoma.

 

As previously stated, restrictions of particular Salt Water Disposal wells ("SWD") due to seismic activity has marginally impacted the Company's total brine supply. The Company is developing alternatives to mitigate risk associated with potential future restrictions of individual SWDs. The Board's aim is to not only limit risk exposure, but increase the available brine supply to Iofina's IOsorb® plants. Iofina is working with its partners on strategic plans to reduce risk and potentially expand brine supply and the Board looks forward to updating the market in due course.

 

Under current operating conditions, Iofina expects to produce 250-270MT of crystalline iodine in H1 2016 from its five existing IOsorb® plants. This production estimated range is based on the current injection restrictions at certain sites. Again, the Company is working closely with its partners to mitigate and possibly eliminate these flow restrictions.

 

Iofina continues to consume a large amount of its produced iodine through its halogen derivatives division, Iofina Chemical ("IC"). Iodine use at IC was at record levels for the Company in 2015. The Company is encouraged to report that it has successfully marketed and sold significant quantities of IOsorb® produced iodine into the global market place. In line with other commodities in the global market, the price for iodine has continued to soften. Iodine worldwide is generally sold in US Dollars. The strengthening of the US Dollar versus other global currencies has further impacted iodine pricing.

 

In order to manage the impact of these extraneous fluctuations, the Company has successfully cut expenses, reduced production and corporate costs and continues to investigate additional cost cutting measures. These measures are expected to protect the Company's cash position and have a positive impact on the Company's gross margins for the current financial year as it moves toward cashflow positive operations.

 

 

 

 

Commenting, President and CEO Dr. Tom Becker, stated: 

 

"While the Board is encouraged by the sizeable year-on-year iodine production increase and overall operational gains, with the backdrop of an uncertain capital markets and commodity climate, 2016 will be a year of prudency and value protection. The Company remains focused on seeking out ways to streamline efficiencies and mitigate risk, while expanding production at its current plants and future operations." 

 

 

For further information, please contact:

 

Dr. Tom Becker, CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Christopher Raggett/Giles Rolls/Joanna Scott

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Media Contact:

Dominic Barretto/Harriet Jackson

Yellow Jersey PR Limited

Tel: +44 (0)7768 537 739

About Iofina:

Iofina specializes in the exploration and production of iodine, iodine specialty chemical derivatives and produced water. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America based on Iofina's WET® IOsorb® technology. Iofina has production operations in the United States, specifically in Montana, Kentucky and Oklahoma. It has complete vertical integration from the production of iodine in the field to the manufacture of the chemical end-products derived from iodine to the consumer and the recycling of iodine using iodinated side-streams from waste chemical processes. Iofina utilizes its portfolio of patented and patent pending technology, proprietary methods and trademarks throughout all business lines.

www.iofina.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBIGDBCGBBGLR
Date   Source Headline
2nd May 20247:00 amRNSFinal Results
16th Apr 20247:00 amRNSQ1 2024 Corporate Update
17th Jan 20247:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSQ4 2023 Corporate Update
30th Nov 20237:00 amRNSIO#9 Update
20th Oct 20237:00 amRNSSigned Agreement for IO#10 and Q3 2023 Update
11th Sep 20237:00 amRNSInterim Results
25th Aug 20235:00 pmRNSHolding(s) in Company
24th Jul 20235:00 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSH1 Update and Updated Loan Facilities
14th Jun 20232:00 pmRNSResult of AGM
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating
9th May 20237:00 amRNSNotice of AGM
4th May 20237:00 amRNSInvestor Presentation
28th Apr 20234:45 pmRNSHolding(s) in Company
28th Apr 20237:00 amRNSGrant of Share Options
25th Apr 20237:00 amRNS2022 FULL YEAR RESULTS
12th Apr 20237:00 amRNSProduction Update
20th Feb 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSMarket Update
28th Dec 20222:34 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSIofina Chemical Awarded ISO Certification
21st Nov 20227:00 amRNSChange of Adviser
28th Oct 20227:00 amRNSFinalised Terms for IO9 & Q3 Production Update
26th Sep 202211:06 amRNSSecond Price Monitoring Extn
26th Sep 202211:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSInterim Results
8th Jul 20227:00 amRNSAdditional Loan Facilities and H1 Update
5th Jul 20228:54 amRNSHolding(s) in Company
22nd Jun 20222:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSAppointment of Chrystal Capital Partners LLP
27th May 20227:00 amRNSNotice of AGM
26th May 20224:15 pmRNSHolding(s) in Company
26th May 20222:15 pmRNSHolding(s) in Company
24th May 20226:15 pmRNSHolding(s) in Company
20th May 20227:10 amRNSInvestor Presentation
18th May 20227:00 amRNSHolding(s) in Company
9th May 20227:00 amRNSFinal Results
5th May 20227:00 amRNSHolding(s) in Company
28th Apr 20228:38 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSQ1 2022 and IO#9 Update
8th Apr 20221:07 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSHolding(s) in Company
14th Mar 20227:00 amRNSDirector/PDMR Shareholding
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSGrant of Share Options
8th Mar 20228:51 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.